Discover
ABEO
Abeona Therapeutics Inc.
6.05
2 x 4.59
2 x 7.89
bid
ask
-
0.13
2.10%
2 @ 07:08 AM
6.06 +0.01 (0.17%)
| Ytd | 14.80% | |
| 1y | 8.62% |
6.04
day range
6.39
4.00
52 week range
7.54
| Open | 6.17 | Prev Close | 6.18 | Low | 6.04 | High | 6.39 | Mkt Cap | 344.82M |
| Vol | 2.06M | Avg Vol | 1.15M | EPS | 0.95 | P/E | 6.37 | Forward P/E | -3.84 |
| Beta | 1.50 | Short Ratio | 10.79 | Inst. Own | 77.54% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 5.61 | 200-d Avg | 5.20 | 1yr Est | 16.75 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -0.38 | -0.31 | 0.07 | 18.42% |
| 2024-08-12 | 2024-06 | -0.33 | -0.75 | -0.42 | -127.27% |
| 2024-05-15 | 2024-03 | -0.47 | -0.53 | -0.06 | -12.77% |
| 2024-03-18 | 2023-12 | -0.51 | -0.64 | -0.13 | -25.49% |
| 2023-11-13 | 2023-09 | -0.53 | -0.48 | 0.05 | 9.43% |
| 2023-08-08 | 2023-06 | -0.66 | -0.44 | 0.22 | 33.33% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-25 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-31 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-29 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2024-08-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-12 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-03 | HC Wainwright & Co. | Upgrade | Buy |
Profile
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-08-25 | ALLAND LEILA | Director | 118.27K | Stock Award(Grant) |
| 2024-08-25 | ALVINO MARK J. | Director | 72.33K | Stock Award(Grant) |
| 2024-08-25 | AMOROSO MICHAEL | Director | 144.37K | Stock Award(Grant) |
| 2024-08-25 | CHARLES FAITH L. | Director | 113.73K | Stock Award(Grant) |
| 2024-08-12 | CROMBEZ ERIC M.D. | Director | 11.04K | Stock Award(Grant) |
| 2024-07-07 | O'MALLEY BRENDAN M | General Counsel | 280.36K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Suvretta Capital Management, LLC | 3.69M | 20.93M | 8.48% |
| 2024-09-29 | Nantahala Capital Management, LLC | 3.43M | 19.50M | 7.90% |
| 2024-09-29 | Adage Capital Partners GP L.L.C. | 3.25M | 18.46M | 7.48% |
| 2024-09-29 | Millennium Management Llc | 2.30M | 13.07M | 5.29% |
| 2024-09-29 | Vanguard Group Inc | 2.01M | 11.40M | 4.62% |
| 2024-09-29 | Vivo Capital, LLC | 1.84M | 10.47M | 4.24% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.23M | 7.00M | 2.84% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 703.06K | 3.99M | 1.62% |
| 2024-09-29 | Simplify Exchange Traded Fds-Simplify Propel Opportunities ETF | 408.58K | 2.32M | 0.94% |
| 2024-09-29 | abrdn Life Sciences Investors | 327.00K | 1.86M | 0.75% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 229.14K | 1.30M | 0.53% |
| 2024-10-30 | iShares Micro Cap ETF | 89.30K | 507.21K | 0.21% |
Dividend
| Dividend | Date |
|---|---|
| 0.593 | 2000-03-31 |
Split
| Split | Date |
|---|---|
| 1 : 25 | 2022-07-05 |
| 1 : 50 | 2014-10-24 |
| 0.2 : 1 | 2006-06-05 |
| 0.05 : 1 | 1998-06-18 |
| 0.05 : 1 | 1998-06-05 |
| 1 : 2 | 1992-04-16 |